CG
VRTX icon

Caprock Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Caprock Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
33,721
+3,714
+12% +$1.65M 0.32% 58
2026
Q1 		$13.4M Buy
30,007
+984
+3% +$459K 0.33% 53
2025
Q4 		$13.2M Buy
29,023
+3,807
+15% +$1.64M 0.28% 59
2025
Q3 		$9.86M Buy
+25,216
New +$10.5M 0.24% 72
2025
Q1 		$14.5M Sell
29,997
-9,187
-23% -$4.28M 0.44% 40
2024
Q4 		$15.8M Buy
39,184
+1,096
+3% +$508K 0.52% 30
2024
Q3 		$17.7M Buy
38,088
+158
+0.4% +$75.9K 0.64% 24
2024
Q2 		$17.8M Buy
37,930
+35,045
+1,215% +$15.2M 0.72% 20
2024
Q1 		$1.21M Buy
2,885
+11
+0.4% +$4.65K 0.07% 211
2023
Q4 		$1.17M Buy
2,874
+306
+12% +$113K 0.07% 217
2023
Q3 		$893K Buy
2,568
+44
+2% +$15.4K 0.07% 234
2023
Q2 		$888K Buy
2,524
+257
+11% +$86.6K 0.07% 236
2023
Q1 		$714K Sell
2,267
-49
-2% -$14.7K 0.06% 268
2022
Q4 		$669K Buy
2,316
+152
+7% +$46.3K 0.06% 231
2022
Q3 		$627K Buy
2,164
+41
+2% +$11.8K 0.06% 232
2022
Q2 		$598K Sell
2,123
-1,241
-37% -$332K 0.06% 239
2022
Q1 		$878K Sell
3,364
-54
-2% -$12.8K 0.08% 198
2021
Q4 		$751K Buy
3,418
+1,955
+134% +$380K 0.06% 218
2021
Q3 		$265K Sell
1,463
-342
-19% -$66.8K 0.02% 417
2021
Q2 		$364K Buy
1,805
+325
+22% +$68K 0.03% 313
2021
Q1 		$318K Sell
1,480
-162
-10% -$35.6K 0.03% 318
2020
Q4 		$388K Sell
1,642
-452
-22% -$104K 0.04% 273
2020
Q3 		$570K Buy
2,094
+230
+12% +$63.5K 0.08% 186
2020
Q2 		$541K Buy
+1,864
New +$505K 0.08% 183

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Caprock Group's VRTX Position: Q2 2026 in Review

Caprock Group increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $1.65M and bringing the position to 33,721 shares worth $16.8M. The position accounts for 0.32% of the portfolio, ranked #58.

Caprock Group first reported a position in VRTX in Q2 2020 and has held it in 24 quarters since. The position peaked at $17.8M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Caprock Group held 33,721 shares of Vertex Pharmaceuticals worth $16.8M as of Q2 2026.
  • Caprock Group bought 3,714 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Vertex Pharmaceuticals made up 0.32% of Caprock Group's portfolio in Q2 2026, its #58 holding.
  • Caprock Group first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Caprock Group's Vertex Pharmaceuticals position peaked at $17.8M in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.